



Supplementary Box S1 Search strategy


PubMed	(Naltrexone AND bupropion) AND ("binge-eating disorder" OR "binge-eating disorder"[Mesh] OR "Compulsive Overeating" OR "Eating Disorder" OR "Food Addiction")
EMBASE	(Naltrexone AND bupropion) AND ("binge-eating disorder" OR "Compulsive Overeating" OR "Eating Disorder" OR "Food Addiction")
Cochrane	(Naltrexone OR 'naltrexone'/exp AND bupropion) AND ("binge-eating disorder" OR 'binge eating disorder'/exp OR "Compulsive Overeating" OR "Eating Disorder" OR "Food Addiction")

Supplementary Figure S1 Forest plot of the meta-analysis for body mass index

df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S2 Forest plot of meta-analysis for depression


df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S3 Forest plot of meta-analysis for cholesterol total


df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S4 Forest plot of meta-analysis for low-density lipoprotein

df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S5 Forest plot of meta-analysis for high-density lipoprotein

df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S6 Forest plot of meta-analysis for glycated hemoglobin

df = degrees of freedom; MD = mean difference; NB = naltrexone/bupropion.

Supplementary Figure S7 Critical appraisal of individual studies according to the Cochrane tool for assessing risk of bias in randomized clinical trials

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	Grilo 2021						
	Grilo 2022						
	Grilo 2023						
		Domains: D1: Bias arising from the randomization process. D2: Bias due to deviations from intended intervention. D3: Bias due to missing outcome data. D4: Bias in measurement of the outcome. D5: Bias in selection of the reported result.					Judgement  Low

Supplementary Table S1 Summary of findings

Certainty assessment							Nº of patients		Effect		Certainty
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Bupropion + naltrexone	Placebo	Relative (95%CI)	Absolute (95%CI)	
3	Randomized trials	Not serious	Not serious	Not serious	Very serious [†]	Strong association	77	83	-	MD 1.25 lower (5.61 lower to 3.11 higher)	⊕⊕⊕○ Moderate [†]

[†] The quality of the evidence was downgraded due to the imprecision of the results, since the study had a limited sample size and a wide confidence interval.